TGFB1 and non-small cell lung carcinoma: These combined therapies enhanced antitumor efficacy and reduced toxicity compared to treatments that did not include TGFβ-1 siRNA, showing promise for overcoming drug resistance and improving patient outcomes in NSCLC treatment [88].